Back grey_arrow_rt.gif
 
 
Bristol-Myers Squibb and ADAP Crisis Task Force Announce Enhanced Multi-year Support for AIDS Drug Assistance Programs (ADAPs) and People Living with HIV/AIDS
 
 
  (December 19, 2011) Today, Bristol-Myers Squibb (NYSE: BMY) and the ADAP Crisis Task Force (ACTF) are pleased to announce an enhanced agreement to support the efforts of AIDS Drug Assistance Programs (ADAPs) to provide antiretroviral medicines to people living with HIV and AIDS. Building on a long-standing agreement with the ACTF, this most recent enhanced agreement directly supports ADAP's ability to meet the challenges of increasing patient loads in the face of strained governmental funding.

"Today's announcement of additional pricing considerations further exemplifies Bristol-Myers Squibb's commitment to ADAP and the patients that ADAP serves," said Dwayne Haught, spokesperson for ACTF and manager of the Texas ADAP. "ADAPs are a critical safety net to ensure people living with HIV can continue to receive the HIV treatments they need, and we commend Bristol-Myers Squibb for responding once again to the unprecedented need faced by state ADAPs by providing additional support to help provide people living with HIV access to life-saving HIV medicines."

"Bristol-Myers Squibb has a longstanding commitment to people living with HIV, and we have worked with the ACTF since its inception in 2002 to help ensure patient access to our HIV medications," said Raymond Sacchetti, senior vice president, U.S. Virology, Bristol-Myers Squibb. "We are proud to continue our support of the ADAP Crisis Task Force, and we applaud its ongoing efforts in working with state and federal officials to secure the necessary funding to appropriately meet this critical public health challenge."

In response to ACTF and advocacy community requests, Bristol-Myers Squibb, as part of this accord, has also agreed to further enhancements of its "Access Virology" Patient Assistance Program. By broadening financial eligibility criteria, Bristol-Myers Squibb will be able to extend free medication to a wider range of qualifying patients beginning on January 1, 2012.

About the Bristol-Myers Squibb Access Virology and Co-pay Benefit Programs

Working directly with patients in need of assistance, the Access Virology program evaluates a person's eligibility for multiple prescription assistance programs that are offered, including:

· Patient Assistance Program (PAP) provides:

· Free Bristol-Myers Squibb HIV medicines to eligible patients based on medical and financial needs

· "Fast tracking" of patients currently on an ADAP waiting list through accelerated advancement of their applications

· A streamlined application process and eligibility criteria to help patients applying for medicine access

People living with HIV may apply by calling the Access Virology Program toll-free at (888) 281-8981, Monday Friday from 8 a.m. to 8 p.m. ET or visiting bms.com/documents/products/Access_Virology_Application_100514.pdf to download an application.

· Bristol-Myers Squibb Co-pay Benefit Program:

· Designed for eligible patients with commercial insurance coverage who are prescribed certain Bristol-Myers Squibb medications indicated for the treatment of HIV

· Bristol-Myers Squibb will pay the first $200/month ($2,400/year) of an eligible patient's out-of-pocket co-pay costs for up to one year

Benefit cards are available through healthcare providers or online at

www.bmscopayprogramsusrey.com/ or http://www.bms.com/products/Pages/programs.aspx.

Bristol-Myers Squibb also participates in the Partnership for Prescription Assistance. The Parternship for Prescription Assistance is an innovative program that helps connect patients with no prescription drug coverage to both public and private patient assistance programs. For information on the Partnership for Prescription Assistance, visit www.PPARx.org or call 888-4PPA-NOW (888-477-2669).

About the ACTF and National Alliance of State and Territorial AIDS Directors (NASTAD)

The ADAP Crisis Task Force (ACTF) was formed in December 2002 by NASTAD and a group of state AIDS/ADAP directors concerned about the fiscal crisis facing ADAPs nationwide. The ACTF works in partnership with manufacturers of antiretroviral and other HIV-related medications to reduce drug costs and improve access to medications for clients in the nation's ADAPs. It is estimated that ACTF agreements with companies have saved ADAPs approximately $1.2 billion since 2003. NASTAD provides logistical support for the ACTF.

Founded in 1992, NASTAD is a nonprofit national association of state and territorial health department HIV/AIDS program directors who have programmatic responsibility for administering HIV/AIDS and viral hepatitis health care, prevention, education and supportive services programs funded by state and federal governments. For more information, visit www.NASTAD.org.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

###
For more information, please contact:
Bristol-Myers Squibb
Media:
Cristi Barnett, 609-252-6028, cristi.barnett@bms.com
Investors: John Elicker, 609-252-4611, john.elicker@bms.com
NASTAD
Media: Murray Penner, 202-434-8090, mpenner@NASTAD.org

 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org